{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-080247","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.682264+00:00","generated_at":"2026-05-20T03:23:33.482308+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"RAP-219 Phase 2a fully enrolled; topline data Sept 2025; safety profile clean","bullets":["Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled; topline results expected September 2025.","Consolidated Phase 1 safety data (n=64) shows all TEAEs Grade 1/2, no SAEs; common: headache, dry mouth, brain fog, fatigue.","Upcoming catalysts: initiate Phase 2a in bipolar mania Q3 2025, update on diabetic neuropathic pain program 2H 2025.","Cash, cash equivalents and short-term investments of $285.4M as of March 31, 2025; runway through end of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-080247","json":"https://secwatch.observer/filing/0000950170-25-080247.json","markdown":"https://secwatch.observer/filing/0000950170-25-080247.md","text":"https://secwatch.observer/filing/0000950170-25-080247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000095017025080247/0000950170-25-080247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000095017025080247/rapp-20250602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T03:23:33.482308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}